UPDATE March 2017: ARMS added. Important news: Nivo + Ipi + other agents / MSS and MSI-CRC Immunotherapy Trial

Please feel free to read, share your thoughts, your stories and connect with others!
User avatar
Maia
Posts: 2443
Joined: Fri Aug 24, 2012 8:00 am

Re: UPDATE March 2017: ARMS added. Important news: Nivo + Ipi + other agents / MSS and MSI-CRC Immunotherapy Trial

Postby Maia » Fri Mar 24, 2017 8:47 am

MARCH 2017: *UPDATE ON PROTOCOL for #NCT02060188

The "nivo + ipi + cobi" trial specific for mCRC has added two new arms: with a new combination for MSS:


* a new arm for MSS-CRC:

Nivolumab (Nivo) + Daratumumab (Cohort C6).
Daratumumab is an anti-CD38 monoclonal antibody (FDA approved for multiple myeloma, trade name Darzalex).

* a new arm for for MSI-High CRC:

Nivolumab (Nivo) + BMS-986016 (an anti-LAG-3 antibody, experimental) (Cohort C5)

https://clinicaltrials.gov/ct2/show/study/NCT02060188

Let's remember that this trial (one of the first immuno trial for mCRC) used to be, first, only nivolumab (aPD-1) + ipilimumab (anti CTLA-4), both MS status, and only past October added one arm for MSS: added Cobimetinib, a MEK inhibitor, to nivo and ipi.

The trial also changed its name from
"A Study of Nivolumab, or Nivolumab Combinations in Recurrent and Metastatic Colon Cancer (CheckMate 142)"
to the current
"An Investigational Immuno-therapy Study of Nivolumab, and Nivolumab in Combination With Other Anti-cancer Drugs, in Colon Cancer That Has Come Back or Has Spread (CheckMate 142)"


Return to “Colon Talk - Colon cancer (colorectal cancer) support forum”



Who is online

Users browsing this forum: No registered users and 26 guests